富蘭克林坦伯頓全球投資系列-生技領航基金美元I(acc)股
57.70美元0.52(0.91%)
2025/05/23更新
績效 / 1月0.83%
3月11.27%
1年11.5%
晨星評等-
- 1.現金4.93%
- 2.股票19.30%
- 3.債券0.00%
- 4.其他75.77%
- 1.美國75.48%
- 2.歐元區5.64%
- 3.歐洲不包含歐元區5.43%
- 4.新興亞洲4.06%
- 5.英國3.30%
- 1.Vertex Pharmaceuticals Inc7.92%
- 2.Gilead Sciences Inc7.49%
- 3.Amgen Inc7.27%
- 4.Regeneron Pharmaceuticals Inc5.03%
- 5.Ascendis Pharma AS ADR4.75%
- 6.argenx SE ADR4.06%
- 7.Jazz Pharmaceuticals PLC3.80%
- 8.Merus NV3.08%
- 9.PTC Therapeutics Inc2.90%
- 10.Eli Lilly and Co2.47%
- 1.現金4.93%
- 2.股票19.30%
- 3.債券0.00%
- 4.其他75.77%
- 1.美國75.48%
- 2.歐元區5.64%
- 3.歐洲不包含歐元區5.43%
- 4.新興亞洲4.06%
- 5.英國3.30%
- 1.Vertex Pharmaceuticals Inc7.92%
- 2.Gilead Sciences Inc7.49%
- 3.Amgen Inc7.27%
- 4.Regeneron Pharmaceuticals Inc5.03%
- 5.Ascendis Pharma AS ADR4.75%
- 6.argenx SE ADR4.06%
- 7.Jazz Pharmaceuticals PLC3.80%
- 8.Merus NV3.08%
- 9.PTC Therapeutics Inc2.90%
- 10.Eli Lilly and Co2.47%